<?xml version='1.0' encoding='UTF-8'?><?xml-stylesheet href="http://www.blogger.com/styles/atom.css" type="text/css"?><feed xmlns='http://www.w3.org/2005/Atom' xmlns:openSearch='http://a9.com/-/spec/opensearchrss/1.0/' xmlns:georss='http://www.georss.org/georss' xmlns:gd='http://schemas.google.com/g/2005' xmlns:thr='http://purl.org/syndication/thread/1.0'><id>tag:blogger.com,1999:blog-15644722</id><updated>2011-11-23T22:31:47.430-08:00</updated><title type='text'>Arthritis &amp; Osteoporosis</title><subtitle type='html'>There are over 100 different forms of arthritis.  How to diagnose and manage arthritis requires a comprehensive aproach that includes problem-solving skills.  The clinician must take into account systemic illness, psychosocial stressors, patient and family expectations, etc.  This site is dedicated to the world of arthritis: experiences, treatment and diagnostic advances, procedure skills, visions for the future, and the practice of medicine in general.</subtitle><link rel='http://schemas.google.com/g/2005#feed' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/posts/default'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default?max-results=100'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/'/><link rel='hub' href='http://pubsubhubbub.appspot.com/'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><generator version='7.00' uri='http://www.blogger.com'>Blogger</generator><openSearch:totalResults>43</openSearch:totalResults><openSearch:startIndex>1</openSearch:startIndex><openSearch:itemsPerPage>100</openSearch:itemsPerPage><entry><id>tag:blogger.com,1999:blog-15644722.post-4953188327982347058</id><published>2007-09-20T10:20:00.000-07:00</published><updated>2007-09-20T10:44:04.758-07:00</updated><title type='text'>New Device for Knee OA</title><summary type='text'>This is a recent article form eRheumatology News.  The evidence of improvement not only in symptoms but also in Xray changes and delay to joint replacement is welcome news.  The device appears to be safe, something I cannot say for most non-steroidal anti-inflammatory drugs (NSAIDs)Volume 6, Issue 8, Page 22 (August 2007)Douglas Garland, MDDR. GARLAND is the director of the division of </summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/4953188327982347058/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=4953188327982347058' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/4953188327982347058'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/4953188327982347058'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2007/09/new-device-for-knee-oa.html' title='New Device for Knee OA'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><media:thumbnail xmlns:media='http://search.yahoo.com/mrss/' url='http://bp3.blogger.com/_M4fJ8mXRYk0/RvKwEmrVTSI/AAAAAAAAAAM/gzF_5kveEbE/s72-c/knee+before.gif' height='72' width='72'/><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-9005406081751264764</id><published>2007-05-22T06:46:00.000-07:00</published><updated>2007-05-22T06:53:51.026-07:00</updated><title type='text'>Dispelling Myths About Steroid Joint Injections</title><summary type='text'>This is an article published in the Bulletin on the Rheumatic Diseases. It provides a good, consice reivew of the evidence supporting use of steroid injections into the joints. While somewhat technical, it dispells many of the myths that are propagated in the community. Sadly, many physicians are at fault of perpetuating these myths. Evidence Based Medicine supports the use and safety of this </summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/9005406081751264764/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=9005406081751264764' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/9005406081751264764'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/9005406081751264764'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2007/05/dispelling-myths-about-steroid-joint.html' title='Dispelling Myths About Steroid Joint Injections'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-7194391337450032435</id><published>2007-04-30T20:02:00.000-07:00</published><updated>2007-05-03T08:10:35.924-07:00</updated><title type='text'>AHA Updates NSAID Advice for Heart Disease Patients</title><summary type='text'>From Medscape Medical NewsFebruary 28, 2007 — The American Heart Association (AHA) has issued new guidance discouraging the use of both cyclooxygenase 2 (COX-2) inhibitors and regular nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with known heart disease or those thought to be at high risk of getting heart disease.The statement, published online in the February 26 Rapid Access issue </summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/7194391337450032435/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=7194391337450032435' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/7194391337450032435'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/7194391337450032435'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2007/04/aha-updates-nsaid-advice-for-heart.html' title='AHA Updates NSAID Advice for Heart Disease Patients'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-115265097182572601</id><published>2006-07-11T13:33:00.000-07:00</published><updated>2006-07-11T13:49:31.840-07:00</updated><title type='text'>Long-Term Adalimumab (Humira) Safe for Rheumatoid Arthritis Patients</title><summary type='text'>NEW YORK (Reuters Health) Jul 10 - Long-term treatment of rheumatoid arthritis (RA) with adalimumab is generally safe and well tolerated, according to a report in the July issue of the Annals of the Rheumatic Diseases.More than one million patients have been treated with tumor necrosis factor antagonists, including adalimumab, the authors explain, but safety concerns persist.Dr. Michael H. Schiff</summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/115265097182572601/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=115265097182572601' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/115265097182572601'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/115265097182572601'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2006/07/long-term-adalimumab-humira-safe-for.html' title='Long-Term Adalimumab (Humira) Safe for Rheumatoid Arthritis Patients'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-115253731340131661</id><published>2006-07-10T06:13:00.000-07:00</published><updated>2006-07-10T06:15:13.416-07:00</updated><title type='text'>NOF Scientific Statement on Osteonecrosis of the Jaw and Bisphosphonates</title><summary type='text'>Osteonecrosis of the Jaw (ONJ) June 14, 2006 What is it?Recently reports have described a dental condition, ONJ, in which bone in the lower jaw or less commonly the upper jaw becomes exposed, typically after a dental extraction or some other trauma to the jaw, and the wound that occurs fails to heal in the usual time frame. Infection in the area can occur and the area may be painful. This can </summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/115253731340131661/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=115253731340131661' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/115253731340131661'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/115253731340131661'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2006/07/nof-scientific-statement-on.html' title='NOF Scientific Statement on Osteonecrosis of the Jaw and Bisphosphonates'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-114704408066293153</id><published>2006-05-07T16:03:00.000-07:00</published><updated>2006-05-18T06:42:14.906-07:00</updated><title type='text'>Glucosamine: where are we now?</title><summary type='text'>The GAIT trial (Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis) was recently published in the New England Journal of Medicine. The study was designed to answer the question of wether or not Glucosamine has any benefit in treating patients with osteoarthritis. It compared three treatment groups: Glucosamine, Chondroitin, Glucosamine and Chondroitin, </summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/114704408066293153/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=114704408066293153' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/114704408066293153'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/114704408066293153'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2006/05/glucosamine-where-are-we-now.html' title='Glucosamine: where are we now?'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-114679153912351702</id><published>2006-05-04T18:11:00.000-07:00</published><updated>2006-05-13T05:48:40.846-07:00</updated><title type='text'>Joint Injections in Rheumatoid Arthritis</title><summary type='text'>Over the last several months there has been a few articles that highlighted the benefits of intraarticular (IA) corticosteroid injections (cortisone shots to the joint). My bias in clinical practice has been for sometime to opt for IA injections in lieu of oral or intramuscular corticosteroid injections. I feel the clinical response is more robust and there appear to be less systemic side effects</summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/114679153912351702/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=114679153912351702' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/114679153912351702'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/114679153912351702'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2006/05/joint-injections-in-rheumatoid.html' title='Joint Injections in Rheumatoid Arthritis'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-114165931651145402</id><published>2006-03-06T07:34:00.000-08:00</published><updated>2006-03-25T04:01:25.706-08:00</updated><title type='text'>Ritiximab (Rituxan) for Refractory Moderate to Severe Rheumatoid Arthritis</title><summary type='text'>from Medscape Medical NewsRituximab (Rituxan) for Refractory Moderate to Severe Rheumatoid ArthritisOn February 28, the FDA approved a new indication for rituximab injection (Rituxan, made by Genentech, Inc, and Biogen Idec, Inc, and marketed as MabThera in Europe), allowing its use in combination with methotrexate to reduce signs and symptoms of moderately to severely active rheumatoid arthritis</summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/114165931651145402/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=114165931651145402' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/114165931651145402'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/114165931651145402'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2006/03/ritiximab-rituxan-for-refractory.html' title='Ritiximab (Rituxan) for Refractory Moderate to Severe Rheumatoid Arthritis'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-113941119188017961</id><published>2006-02-08T07:05:00.000-08:00</published><updated>2006-02-08T07:06:31.893-08:00</updated><title type='text'>Local steroid injection better than surgery for carpal tunnel syndrome</title><summary type='text'>from Medscape Medical Newsby Laurie Barclay, MDFeb. 3, 2005 — Local steroid injection initially may be better than surgery for carpal tunnel syndrome (CTS), according to the results of the first randomized trial published in the February issue of Arthritis &amp; Rheumatism. At three months, symptomatic relief was better with injection; by six months, surgery was not statistically significantly better</summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/113941119188017961/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=113941119188017961' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/113941119188017961'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/113941119188017961'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2006/02/local-steroid-injection-better-than.html' title='Local steroid injection better than surgery for carpal tunnel syndrome'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-113638578847338563</id><published>2006-01-04T06:37:00.000-08:00</published><updated>2006-01-04T06:43:08.486-08:00</updated><title type='text'>Small weight loss better than drugs for improving OA pain, stiffness, function</title><summary type='text'>From Jointandbone.org, by Janis Kelly. San Diego, CA - Losing even a small amount of weight can reduce pain, relieve stiffness, and improve daily functioning for patients with mild to moderate knee osteoarthritis (OA), in some cases more effectively than a coxib, Dr Susan J Bartlett (Johns Hopkins Medical Institutions, Baltimore, MD) reported at the 2005 ACR/ARHP Annual Scientific Meeting [1]."A </summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/113638578847338563/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=113638578847338563' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/113638578847338563'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/113638578847338563'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2006/01/small-weight-loss-better-than-drugs.html' title='Small weight loss better than drugs for improving OA pain, stiffness, function'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-113630223328250890</id><published>2006-01-03T07:29:00.000-08:00</published><updated>2006-01-04T14:05:39.483-08:00</updated><title type='text'>Adalimumab Plus Methotrexate Superior to Monotherapy for RA</title><summary type='text'>NEW YORK (Reuters Health) Dec 30 - For patients with early, aggressive rheumatoid arthritis (RA), treatment with a combination of adalimumab (Humira, Abbott) and methotrexate leads to a better clinical response than treatment with either agent alone, according to results of the PREMIER study.Dr. Ferdinand C. Breedveld, from Leiden University Medical Center in the Netherlands, and his colleagues </summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/113630223328250890/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=113630223328250890' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/113630223328250890'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/113630223328250890'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2006/01/adalimumab-plus-methotrexate-superior.html' title='Adalimumab Plus Methotrexate Superior to Monotherapy for RA'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-113587197790299221</id><published>2005-12-29T07:57:00.000-08:00</published><updated>2005-12-29T07:59:37.916-08:00</updated><title type='text'>Exercise, Calcium Supplementation May Improve BMD in Postmenopausal Women</title><summary type='text'>News Author: Laurie Barclay, MDFrom Medscape Medical News.Dec. 28, 2005 — Exercise and calcium supplementation improve bone mineral density (BMD) in postmenopausal women, according to the results of a 4-year study reported in the December issue of Osteoporosis International."The good news is these long-term data confirmed the potent combination of improved nutrition and increased physical </summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/113587197790299221/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=113587197790299221' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/113587197790299221'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/113587197790299221'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2005/12/exercise-calcium-supplementation-may.html' title='Exercise, Calcium Supplementation May Improve BMD in Postmenopausal Women'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-113586743060599787</id><published>2005-12-29T06:42:00.000-08:00</published><updated>2005-12-29T06:43:50.616-08:00</updated><title type='text'>FDA OKs Bristol-Myers Drug for Rheumatoid Arthritis</title><summary type='text'>LOS ANGELES (Reuters) Dec 27 - Bristol-Myers Squibb Co. said on Friday that it has won U.S. approval to sell a new type of drug for treating rheumatoid arthritis.The drug, Orencia (abatacept), is the first approved T-cell co-stimulation modulator. It is administered by monthly intravenous infusion.Orencia was approved for treating moderate to severe cases of rheumatoid arthritis that do not </summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/113586743060599787/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=113586743060599787' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/113586743060599787'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/113586743060599787'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2005/12/fda-oks-bristol-myers-drug-for.html' title='FDA OKs Bristol-Myers Drug for Rheumatoid Arthritis'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-113579258018118470</id><published>2005-12-28T09:54:00.000-08:00</published><updated>2005-12-28T09:56:20.193-08:00</updated><title type='text'>Topical Diclofenac Reduces Pain of Knee Osteoarthritis</title><summary type='text'>From Medscape Medical News.NEW YORK (Reuters Health) Dec 22 - Topical diclofenac gel applied four times daily relieves symptoms of osteoarthritis (OA) of knee, results of a German study demonstrate.Oral nonsteroidal anti-inflammatory drugs (NSAIDs) have considerable gastrointestinal toxicity, Dr. Fritz U. Niethard and colleagues note in the Journal of Rheumatology for December, whereas systemic </summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/113579258018118470/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=113579258018118470' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/113579258018118470'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/113579258018118470'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2005/12/topical-diclofenac-reduces-pain-of.html' title='Topical Diclofenac Reduces Pain of Knee Osteoarthritis'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-113448499340329237</id><published>2005-12-13T06:42:00.000-08:00</published><updated>2005-12-13T06:43:13.413-08:00</updated><title type='text'>Glucocorticoid Injection Appears Helpful in Rheumatoid Arthritis</title><summary type='text'>From Medscape Medical newsBy David DouglasNEW YORK (Reuters Health) Dec 08 - Intra-articular glucocorticoid injections appear to protect cartilage in patients with rheumatoid arthritis (RA), Swedish researchers report in the December issue of Annals of the Rheumatic Diseases. In addition, subsequent bed rest seems to improve results.Dr. Tomas Weitoft of Gavle Hospital and colleagues note that </summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/113448499340329237/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=113448499340329237' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/113448499340329237'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/113448499340329237'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2005/12/glucocorticoid-injection-appears.html' title='Glucocorticoid Injection Appears Helpful in Rheumatoid Arthritis'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-113344947297312640</id><published>2005-12-01T07:03:00.000-08:00</published><updated>2005-12-01T07:04:32.986-08:00</updated><title type='text'>TNF inhibitors, MTX reduce RA cardiovascular deaths</title><summary type='text'>Nov 25, 2005 Janis KellySan Diego, CA - TNF inhibitors and methotrexate (MTX) decrease the risk of death, especially cardiovascular (CV) death, in rheumatoid-arthritis (RA) patients, whereas prednisone increases mortality, Kaleb Michaud (Stanford University, CA) reported at the 2005 ACR/ARHP Annual Scientific Meeting [1].According to Michaud, anti-TNF use was associated with a reduced risk of </summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/113344947297312640/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=113344947297312640' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/113344947297312640'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/113344947297312640'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2005/12/tnf-inhibitors-mtx-reduce-ra.html' title='TNF inhibitors, MTX reduce RA cardiovascular deaths'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-113216611733575855</id><published>2005-11-16T10:34:00.000-08:00</published><updated>2005-11-16T10:35:17.346-08:00</updated><title type='text'>COX-2 Inhibitors and Other NSAIDs Increase Mortality in Acute MI Patients</title><summary type='text'>From Medscape Medical News by Martha KerrNov. 15, 2005 (Dallas) — An analysis of data from a nationwide registry shows that the use of selective cyclooxygenase-2 (COX-2) inhibitors is contraindicated in acute myocardial infarction (MI) patients. The data also show that only low doses of nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) should be used in this population, because the drugs</summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/113216611733575855/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=113216611733575855' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/113216611733575855'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/113216611733575855'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2005/11/cox-2-inhibitors-and-other-nsaids.html' title='COX-2 Inhibitors and Other NSAIDs Increase Mortality in Acute MI Patients'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-113171647355348556</id><published>2005-11-11T05:39:00.000-08:00</published><updated>2005-11-11T05:41:13.566-08:00</updated><title type='text'>FDA Safety Labeling Changes: Celebrex</title><summary type='text'>News Author: Yael WaknineFrom Medscape Medical NewsNov. 9, 2005 — The U.S. Food and Drug Administration (FDA) has approved safety labeling revisions to advise that celecoxib therapy is linked to risks for cardiovascular, gastrointestinal, renal, and dermatologic adverse events.Celecoxib (Celebrex) Linked to Multiple Adverse EventsOn July 29, the FDA approved safety labeling revisions for the </summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/113171647355348556/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=113171647355348556' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/113171647355348556'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/113171647355348556'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2005/11/fda-safety-labeling-changes-celebrex.html' title='FDA Safety Labeling Changes: Celebrex'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-113154459010177517</id><published>2005-11-09T05:54:00.000-08:00</published><updated>2005-11-09T05:56:30.113-08:00</updated><title type='text'>Folic Acid Reduces Methotrexate Efficacy</title><summary type='text'>By Anne Harding NEW YORK (Reuters Health) Nov 08 - A new study provides additional evidence that folic acid can reduce the efficacy of methotrexate.Methotrexate inhibits dihydrate folate reductase and thus reduces levels of folate in the body, Dr. Dinesh Khanna of the University of Cincinnati in Ohio noted in an interview with Reuters Health. This can lead to mouth sores and other side </summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/113154459010177517/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=113154459010177517' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/113154459010177517'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/113154459010177517'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2005/11/folic-acid-reduces-methotrexate.html' title='Folic Acid Reduces Methotrexate Efficacy'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-113154153219633418</id><published>2005-11-09T05:04:00.000-08:00</published><updated>2005-11-09T05:06:52.200-08:00</updated><title type='text'>New guidelines for steroid-induced osteoporosis</title><summary type='text'>Rheumawire news (from Jointandbone.org)November 7, 2005 Janis KellyBrussels, Belgium - Dr Jean-Pierre Devogelaer and colleagues in the Belgian Bone Club report a set of evidence-based guidelines for the prevention and treatment of glucocorticoid (GC)-induced osteoporosis in Osteoporosis International [1]. The guidelines largely validate what has been standard practice for many clinicians but </summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/113154153219633418/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=113154153219633418' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/113154153219633418'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/113154153219633418'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2005/11/new-guidelines-for-steroid-induced.html' title='New guidelines for steroid-induced osteoporosis'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-113103023838598417</id><published>2005-11-03T07:01:00.000-08:00</published><updated>2005-11-03T07:03:58.396-08:00</updated><title type='text'>Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists.</title><summary type='text'>From Biocritique.comThe goal of this study was to determine the cancer pattern of patients with rheumatoid arthritis (RA) from both prevalent and incident RA cohorts and understand the risk of solid cancer after treatment with tumor necrosis factor (TNF) inhibitors. The investigators took a population based study of 3 RA cohorts (1 prevalent), admitted to the hospital 1990 – 2003 (N=53,060), 1 </summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/113103023838598417/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=113103023838598417' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/113103023838598417'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/113103023838598417'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2005/11/risks-of-solid-cancers-in-patients.html' title='Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists.'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-113087173808299976</id><published>2005-11-01T10:59:00.000-08:00</published><updated>2005-11-01T11:02:18.096-08:00</updated><title type='text'>Exercise May Improve Knee Cartilage in Patients at Risk for [Osteoarthritis]</title><summary type='text'>Author: Laurie Barclay, MD. From: Medscape Oct. 28, 2005 — Exercise improves the glycosaminoglycan (GAG) content of the knee in patients at risk for osteoarthritis (OA), according to the results of a randomized trial reported in the November issue of Arthritis &amp; Rheumatism."The effects of exercise on human cartilage are largely unknown because, until recently, investigators have been unable to </summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/113087173808299976/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=113087173808299976' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/113087173808299976'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/113087173808299976'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2005/11/exercise-may-improve-knee-cartilage-in.html' title='Exercise May Improve Knee Cartilage in Patients at Risk for [Osteoarthritis]'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-113041672611992234</id><published>2005-10-27T05:32:00.000-07:00</published><updated>2005-10-27T05:38:46.130-07:00</updated><title type='text'>Steroids for Rheumatoid Arthritis</title><summary type='text'>Steroids for RA: The argument heats up againOct 18, 2005by Janis Kelly, RheumawireSt Louis, MO and Rochester, MN - A group of researchers from the Mayo Clinic propose in an editorial in the October 2005 issue of the Journal of Rheumatology that, far from harming the cardiovascular (CV) system, glucocorticoids (GCs) "might actually reduce the risk of cardiovascular disease (CVD) in patients with [</summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/113041672611992234/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=113041672611992234' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/113041672611992234'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/113041672611992234'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2005/10/steroids-for-rheumatoid-arthritis.html' title='Steroids for Rheumatoid Arthritis'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-112912524482195958</id><published>2005-10-12T06:53:00.000-07:00</published><updated>2005-10-12T06:54:04.826-07:00</updated><title type='text'>Aromatase Inhibitors and the Syndrome of Arthralgias With Estrogen Deprivation</title><summary type='text'>From ARTHRITIS &amp; RHEUMATISM Research News AlertsAromatase Inhibitors and the Syndrome of Arthralgias With Estrogen DeprivationPosted 10/10/2005Recent evidence suggests caution in prescribing hormone therapy for breast cancer and sheds new light on "menopausal arthritis."One of the most effective new treatments for breast cancer is a hormone therapy. Aromatase inhibitors work by powerfully </summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/112912524482195958/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=112912524482195958' title='1 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112912524482195958'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112912524482195958'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2005/10/aromatase-inhibitors-and-syndrome-of.html' title='Aromatase Inhibitors and the Syndrome of Arthralgias With Estrogen Deprivation'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>1</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-112880037003246603</id><published>2005-10-08T12:39:00.000-07:00</published><updated>2005-10-08T12:39:30.033-07:00</updated><title type='text'>Long-Term NSAID Use Cuts Oral Cancer Risk, but Raises Cardiovascular Mortality</title><summary type='text'> By Anthony J. Brown, MDNEW YORK (Reuters Health) Oct 07 - Long-term use of NSAIDs can reduce the risk of oral cancer, but careful monitoring is required because these drugs may also raise the risk of death from cardiovascular disease, according to a report in the October 7th online issue of The Lancet."When we analyzed the data, NSAID use was tied to a reduced risk of oral cancer, similar to </summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/112880037003246603/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=112880037003246603' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112880037003246603'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112880037003246603'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2005/10/long-term-nsaid-use-cuts-oral-cancer.html' title='Long-Term NSAID Use Cuts Oral Cancer Risk, but Raises Cardiovascular Mortality'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-112879990563264462</id><published>2005-10-08T12:29:00.000-07:00</published><updated>2005-10-08T12:31:45.640-07:00</updated><title type='text'>FDA Approves Humira for Psoriatic Arthritis</title><summary type='text'>by Yael Waknine, Medscape NewsAdalimumab (Humira) Approved for Psoriatic Arthritis and Early RA On Oct. 3, the FDA approved a new indication and expanded the rheumatoid arthritis (RA) indication for adalimumab subcutaneous injection (Humira, made by Abbott Laboratories, Inc.), allowing its use in the treatment of psoriatic arthritis, and as first-line treatment for severe, active, and progressive</summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/112879990563264462/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=112879990563264462' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112879990563264462'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112879990563264462'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2005/10/fda-approves-humira-for-psoriatic.html' title='FDA Approves Humira for Psoriatic Arthritis'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-112835517200124382</id><published>2005-10-03T08:58:00.000-07:00</published><updated>2005-10-03T08:59:32.003-07:00</updated><title type='text'>Infliximab May Reduce Progression of Ankylosing Spondylitis</title><summary type='text'>By Megan RauscherNEW YORK (Reuters Health) Sept 30 - Treatment with the tumor necrosis factor (TNF) alpha antibody infliximab may slow radiographic progression of spinal lesions in patients with ankylosing spondylitis (AS), German researchers report in the October issue of Annals of the Rheumatic Diseases.As senior investigator Dr. Juergen Braun from Ruhr University in Bochum, told Reuters Health</summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/112835517200124382/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=112835517200124382' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112835517200124382'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112835517200124382'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2005/10/infliximab-may-reduce-progression-of.html' title='Infliximab May Reduce Progression of Ankylosing Spondylitis'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-112835502948438722</id><published>2005-10-03T08:56:00.000-07:00</published><updated>2005-10-03T08:57:09.490-07:00</updated><title type='text'>TNF Blockers Do Not Raise Cancer Risk</title><summary type='text'>NEW YORK (Reuters Health) Sept 27 - Although rheumatoid arthritis (RA) is associated with an increased risk of hematopoietic malignancies, tumor necrosis factor (TNF) antagonists used in the treatment of RA do not appear to raise the risk of lymphoma or solid tumors, Swedish investigators report.Much of the data regarding cancer risk in RA patients are relatively old, Dr. Johan Askling, from </summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/112835502948438722/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=112835502948438722' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112835502948438722'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112835502948438722'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2005/10/tnf-blockers-do-not-raise-cancer-risk.html' title='TNF Blockers Do Not Raise Cancer Risk'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-112593507586951368</id><published>2005-09-05T07:56:00.000-07:00</published><updated>2005-09-05T08:44:35.876-07:00</updated><title type='text'>Ibuprofen and Aspirin Combination Increase rate of Heartattacks</title><summary type='text'>Ibuprofen may abrogate the benefits of aspirin when used for secondary prevention of myocardial infarction.M Hudson, M Baron, E Rahme, L PiloteJ Rheumatol 2005 8;32(8):1589-93\ From Biocritique.com The paper by Catella-Lawson (NEJM-2001) first alerted us to the potential interaction of ibuprofen and aspirin with the potential of increased cardiac events. MacDonald (Lancet-2003) in a meta-analysis</summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/112593507586951368/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=112593507586951368' title='1 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112593507586951368'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112593507586951368'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2005/09/ibuprofen-and-aspirin-combination.html' title='Ibuprofen and Aspirin Combination Increase rate of Heartattacks'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>1</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-112554010118590803</id><published>2005-08-31T18:07:00.000-07:00</published><updated>2005-10-12T08:23:40.510-07:00</updated><title type='text'>On the Myth About Steroid Joint Injections</title><summary type='text'>Where does the evidence come from?When I was fellow, I learned from my mentor Dr. Roy Altman, that joint injections of glucocorticoids (anti-inflammatory steroids) could be administered into a joint about once a month. Now, that's odd, I thought. When I was a resident in internal medicine I was informed by the Orthopedic Attending that one could only inject a given joint about 3 times, ever. Dr. </summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/112554010118590803/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=112554010118590803' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112554010118590803'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112554010118590803'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2005/08/on-myth-about-steroid-joint-injections.html' title='On the Myth About Steroid Joint Injections'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-112545729301944944</id><published>2005-08-30T20:00:00.000-07:00</published><updated>2005-08-30T20:01:33.020-07:00</updated><title type='text'>On Exercise and Chronic Back Pain</title><summary type='text'>Systematic review: strategies for using exercise therapy to improve outcomes in chronic low back pain.JA Hayden, MW van Tulder, G TomlinsonAnn Intern Med 2005 5;142(9):776-85In this paper, the authors review in a systematic manner the literature on exercise intervention characteristics to identify those exercises (and associated features) that are more likely to improve function, decrease pain </summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/112545729301944944/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=112545729301944944' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112545729301944944'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112545729301944944'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2005/08/on-exercise-and-chronic-back-pain.html' title='On Exercise and Chronic Back Pain'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-112545308323458176</id><published>2005-08-30T18:42:00.000-07:00</published><updated>2005-08-30T18:51:23.236-07:00</updated><title type='text'>ON FIBROMYALGIA: more on accupuncture</title><summary type='text'>A randomized clinical trial of acupuncture compared with sham acupuncture in fibromyalgia.NP Assefi, KJ Sherman, C Jacobsen, J Goldberg, WR Smith, D BuchwaldAnn Intern Med 2005 7;143(1):10-9 This study was conducted in 100 adult community dwellers with Fibromyalgia (FM). They were randomized to receive either real or sham acupuncture (biw) for 12 weeks. The diagnosis of FM was “confirmed” by a </summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/112545308323458176/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=112545308323458176' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112545308323458176'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112545308323458176'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2005/08/on-fibromyalgia-more-on-accupuncture.html' title='ON FIBROMYALGIA: more on accupuncture'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-112502626149616581</id><published>2005-08-25T20:15:00.000-07:00</published><updated>2005-08-30T19:37:36.626-07:00</updated><title type='text'>Woman Complains about Doctor's telling her she is fat</title><summary type='text'>Woman Files Complaint After Doctor Tells Her She's ObeseAttorney General Recommends Doctor Take Education CoursePOSTED: 4:48 pm EDT August 22, 2005ROCHESTER, N.H. -- The state is investigating a Rochester doctor because a patient complained that he bluntly told her she needed to lose weight.Dr. Terry Bennett said that he's outraged by what he calls a baseless complaint. A patient was apparently </summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/112502626149616581/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=112502626149616581' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112502626149616581'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112502626149616581'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2005/08/woman-complains-about-doctors-telling.html' title='Woman Complains about Doctor&apos;s telling her she is fat'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-112498677406695189</id><published>2005-08-25T09:18:00.000-07:00</published><updated>2005-08-25T09:21:44.533-07:00</updated><title type='text'>Dangers from NSAIDs: GI bleeds</title><summary type='text'>NEW YORK (Reuters Health) Aug 24 - Approximately one third of all hospitalizations and deaths related to gastrointestinal bleeding can be attributed to the use of nonsteroidal anti-inflammatory agents (NSAIDs) or aspirin, results of a population-based observational study in Spain suggest. Up to one third of these incidences may be related to low-dose aspirin.To estimate the mortality risk caused </summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/112498677406695189/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=112498677406695189' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112498677406695189'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112498677406695189'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2005/08/dangers-from-nsaids-gi-bleeds.html' title='Dangers from NSAIDs: GI bleeds'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-112532348950945634</id><published>2005-08-22T06:50:00.000-07:00</published><updated>2005-08-29T06:51:29.513-07:00</updated><title type='text'>Patients on antimalarials at risk for myopathy</title><summary type='text'>Aug 22, 2005Janis Kelly"The prevalence of antimalarial myopathy is higher than previously recognized when the muscle-enzyme determination is used as a screening method. When a persistent muscle-enzyme disturbance is observed, a clinical and electromyographic study should be performed periodically to detect earlier the development of a clinical myopathy," say the researchers, led by Dr Enrique </summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/112532348950945634/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=112532348950945634' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112532348950945634'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112532348950945634'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2005/08/patients-on-antimalarials-at-risk-for.html' title='Patients on antimalarials at risk for myopathy'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-112532286594391600</id><published>2005-08-22T06:38:00.000-07:00</published><updated>2005-08-29T06:41:05.953-07:00</updated><title type='text'>Trial shows short-term benefit of corticosteroid injection for sciatica</title><summary type='text'>Aug 22, 2005Allison GandeySouthampton, UK - Overturning previous findings of no demonstrable advantage of epidural steroids, the Wessex Epidural Steroids Trial (WEST) study group reports first-time positive results in its large randomized controlled trial. In an advance access paper published online July 19, 2005 in Rheumatology, the group reports that epidural corticosteroids offer short-term </summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/112532286594391600/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=112532286594391600' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112532286594391600'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112532286594391600'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2005/08/trial-shows-short-term-benefit-of.html' title='Trial shows short-term benefit of corticosteroid injection for sciatica'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-112502695518796833</id><published>2005-08-19T20:27:00.000-07:00</published><updated>2005-08-25T20:29:15.193-07:00</updated><title type='text'>Jury Finds Merck at Fault in Texas Man's Death</title><summary type='text'>JANGLETON, Texas (Reuters) Aug 19 - A jury in the first civil trial against Merck &amp; Co.'s popular painkiller Vioxx on Friday found the pharmaceutical company liable for the 2001 death of a Texas man, awarding his widow a total of more than $250 million.The 12-member jury in Texas state court awarded a $24 million penalty to the widow of Robert Ernst for mental anguish and loss of companionship </summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/112502695518796833/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=112502695518796833' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112502695518796833'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112502695518796833'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2005/08/jury-finds-merck-at-fault-in-texas.html' title='Jury Finds Merck at Fault in Texas Man&apos;s Death'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-112507550237726306</id><published>2005-08-18T09:57:00.000-07:00</published><updated>2005-08-26T10:00:21.503-07:00</updated><title type='text'>Some Glucosamine Products Get Absorbed Poorly</title><summary type='text'>Aug 18, 2005Janis KellyBoston, MA - Osteoarthritis (OA) patients in large numbers began taking glucosamine supplements in the wake of randomized studies showing delayed radiographic progression with glucosamine compared with placebo [1,2]. Subsequent studies cast some doubt on this effect [3], and Dr Beth Anne Biggee (Tufts-New England Medical Center, Boston, MA) and colleagues have now published</summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/112507550237726306/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=112507550237726306' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112507550237726306'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112507550237726306'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2005/08/some-glucosamine-products-get-absorbed.html' title='Some Glucosamine Products Get Absorbed Poorly'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-112541834318732932</id><published>2005-07-26T09:03:00.000-07:00</published><updated>2005-08-30T09:12:23.190-07:00</updated><title type='text'>Flu vaccine in the setting of Rheumatoid Arthritis</title><summary type='text'>Vaccination against influenza in Rheumatoid Arthritis: the effect of disease modifying drugs, including TNF a blockers.I Fomin, D Caspi, V Levy, N Varsano, Y Shalev, D Paran, D Levartovsky, I Litinsky, I Kaufman, I Wigler, E Mendelson, O ElkayamAnn Rheum Dis 2005 7This important paper from Israel addresses questions that often arise in peer to peer discussions among rheumatologists. Does </summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/112541834318732932/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=112541834318732932' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112541834318732932'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112541834318732932'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2005/07/flu-vaccine-in-setting-of-rheumatoid.html' title='Flu vaccine in the setting of Rheumatoid Arthritis'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-112541753525322790</id><published>2005-07-26T08:57:00.000-07:00</published><updated>2005-08-30T08:58:55.260-07:00</updated><title type='text'>Effects of Doxycycline on progression of Osteoarthritis</title><summary type='text'>Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial.KD Brandt, SA Mazzuca, BP Katz, KA Lane, KA Buckwalter, DE Yocum, F Wolfe, TJ Schnitzer, LW Moreland, S Manzi, JD Bradley, L Sharma, CV Oddis, ST Hugenberg, LW HeckArthritis Rheum 2005 7;52(7):2015-25Our current management of osteoarthritis (OA) lacks pharmaceutical agents that</summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/112541753525322790/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=112541753525322790' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112541753525322790'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112541753525322790'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2005/07/effects-of-doxycycline-on-progression.html' title='Effects of Doxycycline on progression of Osteoarthritis'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-112545240423098536</id><published>2005-07-11T18:28:00.000-07:00</published><updated>2005-08-30T18:40:04.236-07:00</updated><title type='text'>ON LUPUS: More on vascular disease</title><summary type='text'>Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome.S Jiménez, MA García-Criado, D Tàssies, JC Reverter, R Cervera, MR Gilabert, D Zambón, E Ros, C Bru, J FontRheumatology (Oxford) 2005 6;44(6):756-61A bimodal pattern of mortality in SLE was recognized nearly 30 years ago (the second peak due to cardiovascular events), accelerated atherosclerosis in </summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/112545240423098536/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=112545240423098536' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112545240423098536'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112545240423098536'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2005/07/on-lupus-more-on-vascular-disease.html' title='ON LUPUS: More on vascular disease'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-112545696001879703</id><published>2005-06-11T19:54:00.000-07:00</published><updated>2005-08-30T19:56:00.023-07:00</updated><title type='text'>ON NSIAIDs:  ALL antiinflammatories seem to be associated with heart disease</title><summary type='text'>Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.J Hippisley-Cox, C CouplandBMJ 2005 6;330(7504):1366 This important observational study is the first of probably more to come suggesting that the increased cardiovascular (CV) risk initially attributed to Cox-2 selective</summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/112545696001879703/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=112545696001879703' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112545696001879703'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112545696001879703'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2005/06/on-nsiaids-all-antiinflammatories-seem.html' title='ON NSIAIDs:  ALL antiinflammatories seem to be associated with heart disease'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-15644722.post-112507465561025890</id><published>2005-02-15T09:43:00.000-08:00</published><updated>2005-08-26T09:45:13.763-07:00</updated><title type='text'>Three Pivotal Trials of COX-2 Inhibitors Released Early by NEJM</title><summary type='text'>Laurie Barclay, MDFeb. 15, 2005 — As the cyclooxygenase-2 (COX-2) inhibitor debate continues, the New England Journal of Medicine has released early three pivotal studies, posted online Feb. 15 and published in the March 15 print issue. Results of the Adenomatous Polyp Prevention on Vioxx (APPROVe) trial led to the withdrawal of rofecoxib from the market, and the results of the Adenoma Prevention</summary><link rel='replies' type='application/atom+xml' href='http://arthritisworld.blogspot.com/feeds/112507465561025890/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=15644722&amp;postID=112507465561025890' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112507465561025890'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/15644722/posts/default/112507465561025890'/><link rel='alternate' type='text/html' href='http://arthritisworld.blogspot.com/2005/02/three-pivotal-trials-of-cox-2.html' title='Three Pivotal Trials of COX-2 Inhibitors Released Early by NEJM'/><author><name>Ricardo Pocurull</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='31' src='http://secure.medem.com/medem/photos/s1794936_p321809_LOGO-aocbv01.jpg'/></author><thr:total>0</thr:total></entry></feed>
